Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 11/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28957232 | 0.85 | HTR6 (0.42) | HTR6MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL19643771 | 0.85 | HTR6 (0.45) | HTR6MAPTMEN1KMT2A | |
| SCHEMBL19127981 | 0.80 | KDM4C (0.42) | ALDH1A1 | |
| SCHEMBL28279804 | 0.79 | ALDH1A1 (0.39) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL768994 | 0.77 | CNR2 (0.43) | ALDH1A1HSD17B10KMT2A | |
| SCHEMBL19656852 | 0.74 | RAB9A (0.34) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL15336103 | 0.74 | SLC6A2 (0.43) | HTR6ALDH1A1KMT2AMAPK1 | |
| SCHEMBL13068172 | 0.73 | NOTUM (0.43) | HTR6ALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL30099065 | 0.71 | HTR6 (0.43) | HTR6ALDH1A1 | |
| SCHEMBL12363788 | 0.71 | NOTUM (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109475530-B | Aminoacyl indazole immunomodulators for treating autoimmune diseases | 洛克菲勒大学 | 2022-03-01 | — | — | CN | disclosed |
| US-20190202811-A1 | AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190202811-A1 | AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2019-07-04 | — | — | US | disclosed |
| EP-3463341-A1 | AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | The Rockefeller University (US) | 2019-04-10 | — | — | EP | disclosed |
| CN-109475530-A | For treating the aminoacyl indazole immunomodulator of autoimmune disease | 洛克菲勒大学 | 2019-03-15 | — | — | CN | disclosed |
| WO-2017205296-A1 | AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205296-A1 | AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202811-A1 | AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | TFPI2, IL4I1, TFPI | HTR6 4542/4885TP53 4842/4885ALDH1A1 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.